Analyst Price Target is $10.00
▲ +119.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genfit in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 119.78% upside from the last price of $4.55.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Genfit. This Buy consensus rating has held steady for over two years.
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.